<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ADEFOVIR DIPIVOXIL</span><br/>(a-de'fo-vir)<br/><span class="topboxtradename">Hepsera<br/></span><b>Classifications:</b> <span class="classification"> antiviral agent</span>; <span class="classification">nucleotide analog</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>10 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Inhibits HBV DNA polymerase (reverse transcriptase) by competing with the natural substrate deoxyadenosine triphosphate and
         by causing DNA chain termination after its incorporation into viral DNA.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>A nucleotide analog with activity against human hepatitis B virus (HBV).</p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of chronic hepatitis B.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to adefovir; untreated or unknown human immunodeficiency virus (HIV); exacerbations of hepatitis B, especially
         in patients who have discontinued anti-hepatitis B therapy; pregnancy (category C); lactation. Safety and efficacy in children
         are not established. Appropriate infant immunizations should be used to prevent neonatal acquisition of the hepatitis B virus.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Decreased cardiac function due to concomitant disease or other drug therapy; elderly; concomitant use of highly nephrotoxic
         drugs; renal dysfunction; co-administration with drugs that reduce renal function or compete for active tubular secretion.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Hepatitis B</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 10 mg q.d.<br/><br/><span class="impairmenttitle">Renal Insufficiency</span><br/>Cl<sub>cr</sub> 2049 mL/min, 10 mg q48h; 1019 mL/min, 10 mg q72h; hemodialysis, 10 mg q7d following dialysis<br/><br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Note that the dosing interval of adefovir should be adjusted in patients with baseline creatinine clearance 
         </li><li>Store in original container at 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span>
<span class="speceff-common">Asthenia,</span> headache. <span class="typehead">GI:</span> Abdominal pain, nausea, flatulence, diarrhea, dyspepsia, exacerbation of hepatitis after discontinuation of therapy, hepatomegaly. <span class="typehead">Metabolic:</span>
<span class="speceff-common">Increased ALT, AST,</span> increased creatine kinase, amylase, lactic acidosis. <span class="typehead">Urogenital:</span>
<span class="speceff-common">Hematuria,</span> glycosuria, increased serum creatinine, nephrotoxicity. <span class="typehead">Other:</span> HIV resistance in patient with unrecognized HIV, hematuria. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Risk of lactic acidosis when used with <span class="classification">nucleoside analogs</span>. <b>Ibuprofen</b> increases bioavailability of adefovir. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Adefovir dipivoxil is a prodrug. 59% of dose is absorbed as active drug. <span class="typehead">Peak:</span> 14 h. <span class="typehead">Distribution:</span> Minimal protein binding. <span class="typehead">Metabolism:</span> Adefovir dipivoxil is rapidly converted to active adefovir. <span class="typehead">Elimination:</span> Primarily excreted in urine. <span class="typehead">Half-Life:</span> 7.5 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Monitor baseline and periodic renal function tests (monitor more often with pre-existing impairment or other risk
            factors for renal impairment); monitor periodic liver function tests, creatinine kinase, serum amylase, and routine blood
            chemistries including serum electrolytes.
         </li>
<li>Withhold drug and notify physician if lactic acidosis is suspected [e.g., hyperventilation, lethargy, plasma pH 56 mol/L (mEq/L)].
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report any of the following to physician: blood in urine, unexplained weakness, or exacerbation of S&amp;S of hepatitis.</li>
<li>Patients who discontinue adefovir should be monitored at repeated intervals over a period of time for hepatic function.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>